US Patent

US8642076 — Lipid containing formulations

Formulation · Assigned to Tekmira Pharmaceuticals Corp · Expires 2027-10-03 · 1y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects lipid-containing formulations for administering nucleic acid-based therapies, such as liposomes and lipoplexes.

USPTO Abstract

Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.

Drugs covered by this patent

Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals

Patent Metadata

Patent number: US8642076
Jurisdiction: US
Classification: Formulation
Expires: 2027-10-03
Drug substance claim: No
Drug product claim: Yes
Assignee: Tekmira Pharmaceuticals Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.